DS
SBC

David Shaw’s SBC Medical Group SBC Stock Holding History

David Shaw’s Portfolio SBC Stock Details SBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-172,500
Closed -$1.8M – 4634
2023
Q1 		$1.8M Hold
172,500
– – ﹤0.01% 2764
2022
Q4 		$1.77M Buy
+172,500
New +$1.75M ﹤0.01% 3032

Other funds holding SBC

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return

David Shaw's SBC Position: Q2 2023 in Review

David Shaw sold out of SBC Medical Group (SBC) in Q2 2023, closing a stake of 172,500 shares — an estimated $1.8M sold.

David Shaw first reported a position in SBC in Q4 2022 and held it in 2 quarters. The position peaked at $1.8M in Q1 2023. 13 funds tracked by Wall St. Rank hold SBC as of Q2 2023.

  • David Shaw reported no remaining SBC Medical Group position as of Q2 2023 after selling out during the quarter.
  • David Shaw sold 172,500 SBC Medical Group shares in Q2 2023, an estimated $1.8M.
  • David Shaw first reported a position in SBC Medical Group in Q4 2022 and held it in 2 quarters.
  • David Shaw's SBC Medical Group position peaked at $1.8M in Q1 2023.
  • 13 funds tracked by Wall St. Rank held SBC Medical Group as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.